Clinical Trials Browser

Enrolling by invitation × Interventional × Brentuximab Vedotin × Clear all

NCT07258680 2025-12-02

BrEto-TCL

Phase 3 Enrolling by invitation

Lymphoma, T-Cell, Peripheral